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James Parkinson (1755-1824) was born in Shoreditch, Middlesex (GB), where he spent
his entire life. He was the oldest son of an apothecary, and in 1771 he started his
apprenticeship to his father. Within 5 years he became a “dressing pupil” at the
London Hospital and in 1784 he was awarded the Membership of the Company of
Surgeons 
1
. During his life he made major scientific contributions in medicine, geolo-
gy and palaeontology, and he also was a prominent political reformer. His first contri-
bution to the medical literature was entitled “Some Accounts of the Effects of
Lightening”, which he read at a meeting of the Medical Society in London in 1787 
1
. In
1817 his “Essay on the Shaking Palsy” was published 
2
. In 5 brief chapters, Parkinson
described a previously unrecognised nervous system disorder in six human cases (of
whom 3 were even not his patients: he had merely observed them during his walks in
the streets), of which a “tremulous motion” seemed one of its hallmarks. Parkinson,
lacking cerebral autopsy material, predicted that the lesions of his patients would be
located in the cervical spinal cord 
3
.  For many years the work of James Parkinson was
almost forgotten. After his death in 1824 (he suffered from a stroke), the medical pro-
fession failed to recognise the disease James Parkinson had described in his essay.
However, when William Gowers in 1886 published “A manual of Diseases of the
Nervous System”, it contained an article on “shaking palsy” or, erroneously, “paraly-
sis agitans” 
1
. Subsequently, it was the French neurologist Jean Martin Charcot who
preferred the eponym of “Parkinson’s Disease” (PD). In the following decades succes-
sive pathological studies (e.g. Lewy, 1914) of patients with PD showed characteristic
brain abnormalities, especially neuronal degeneration in the substantia nigra 
4
. It las-
ted until 1960s that Hornykiewicz discovered that PD patients suffered from extensive
dopamine depletion in the striatum 
5
. In 1967 the “levodopa era” started when Cotzias
showed that orally administered levodopa had a dramatic and sustained effect on the
cardinal motor features of PD: tremor, rigidity and bradykinesia 
6
.
II Motor and non motor features
Since there is no diagnostic biological marker for PD, the clinical diagnosis is entirely
based on the presence of its characteristic motor features 
7
. Thus far few attempts have
been made to develop explicit diagnostic criteria, including features as proposed by
the Parkinson’s Disease Society Brain Bank 
8
. These include bradykinesia (slowness of
initiation of movement with progressive reduction in speed and amplitude of repeti-
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tive actions), and at least one of the following motor features: rigidity, 4-6 Hz rest
tremor and postural instability. Additional supportive criteria for the clinical diagno-
sis PD are a persistent asymmetry of motor features affecting one side most, and an
excellent response to levodopa. Before the appearance of these classic motor features,
there may be a prodromal period in which symptoms and signs occur but do not
specifically indicate PD; these symptoms include depression, musculoskeletal pain,
sensory dysfunction and autonomic disturbance 
9
. Olfactory dysfunction may also be
an early symptom of PD. A recent study on odour discrimination showed that PD
patients could be discriminated from healthy controls with a sensitivity of 88 % and a
specificity of 83 % 
10
. As depression is the most common psychiatric symptom in PD, a
subgroup of patients presents with a depression as the initial disease manifestation 
11
.
Autonomic dysregulation is the most common non motor feature of PD. Orthostatic
hypotension and gastrointestinal complaints are the most common vegetative symp-
toms in PD. Data on the incidence vary between 14-80 % depending on the population
studied and the method used 
12
. Cognitive impairment occurs in 25-40 % to over 90 %
of patients with PD 
13-15
, and dementia is increasingly recognised as an important non-
motor feature of PD, especially in the elderly 
6
. Mental decline in PD is often being
characterised by cognitive slowing, impaired abstract thinking and difficulties with
reasoning. In addition, attentional deficits, visuospatial and executive dysfunction and
memory impairments can be affected even at the early stages of the disease. 
III Diagnosis    
The combination of asymmetry of symptom onset, the presence of a typical resting
tremor, and an excellent response to levodopa best differentiates  (idiopathic) PD from
parkinsonism due to other, more seldom, causes 
6
. Although many signs and symp-
toms are present in all parkinsonian syndromes, they specifically start at different
stages of the disease. These differences in the dynamics of time course become evident
when comparing PD with other, more “atypical” parkinsonian syndromes (e.g.
Multiple System Atrophy, Progressive Supranuclear Palsy), with the latter having a
more rapid functional deterioration 
16
.                                                                         
In clinical practice the differential diagnosis of PD thus primarily includes other pri-
mary inherited or sporadic neurodegenerative syndromes featuring parkinsonism,
parkinsonian syndromes associated with defined diseases, symptomatic parkinsonian
syndromes and monogenetically inherited forms of PD 
17
(see table 1). 
Despite application of explicite diagnostic criteria only 60-70 % of clinical diagnosis of
PD are confirmed by autopsy 
8;14
. Recently 800 patients with clinically PD were
prospectively followed up with repeated clinical assessments; after 6 ± 1.4 years, 8.1 %








Table 1  Differential diagnosis of parkinsonism
Primary neurodegenerative disorders with parkinsonism
Inherited:






7. Dentato Rubral Pallidal Luysian atrophy
8. Pantothenate kinase-associated neurodegeneration
9. Familial depression, alveolar hypoventilation and parkinsonism
10. Neuronal intranuclear inclusion disease
Sporadic:
1. (idiopathic) Parkinson’s Disease
2. Parkinson “plus” syndromes
* Progressive Supranuclear Palsy
* Multiple System Atrophy
* Cortical Basal Ganglionic Degeneration
* Dementia with Lewy Bodies
* M. Alzheimer
* M. Pick
* ALS-Parkinsonism-dementia of Guam
* Hemiparkinsonism with hemiatrophy







1. Toxic (CO, CS2 , manganese)
2. Hepatocerebral degeneration (non-Wilsonian)
3. Endocrine (hypothyroidism, hypoparathyroidism)
4. Mass lesions (AV-malformations, neoplasm)
5. Vascular (vasculitis, infarction, lacunar state)
6. Trauma
7. Autoimmune or inflammatory disease
8. Lack of substrate (hypoxia, hypoglycaemia)
Others:
1. Medication induced (direct or withdrawal)
2. Normal pressure hydrocephalus
Routine imaging of the brain seems not helpful in confirming the clinical diagnosis of
PD, although occasionally PD patients show an increased signal from the substantia
nigra on conventional T2-weighted MRI sequences 
18
. Functional imaging techniques,
like Positron Emission Tomography (PET), provides a means of assessing dopamine
terminal functioning or specific cerebral glucose metabolism in vivo, and allows to
detect preclinical and clinical PD 
19;20
. Several biochemical markers have been tested as
indicators for dopamine deficiency, mostly in the cerebrospinal fluid (CSF). Overall,
the sensitivity and specificity of homovanillic acid (HVA), noradrenaline and 3-
methoxy-4-hydroxyphenylethylglycol in cerebrospinal fluid, and HVA in serum are
too low to use as preclinical or clinical markers for PD 
9
.
IV Prevalence and incidence
PD is the commonest neurodegenerative disease after M. Alzheimer, and it is estima-
ted that in the Netherlands approximately 40.000 people suffer from PD. However,
prevalence estimates of PD in the literature vary widely, merely because of differences
in diagnostic criteria and in the age distribution of the study population 
21
, and ranges
from 150-300 per 100.000 population 
22;23
. 
A population-based cohort study in a general elderly population in the Netherlands
showed increasing prevalence of PD with age, being 1.0 % for those over 65 to 4.3 % in
those over 85 years of age 
21
. Recently the results of 7 population-based studies were
examined separately and pooled to obtain estimates of PD prevalence. The overall
prevalence in persons 65 to 89 years ranged from 1.8-2.6 % 
24
, being the lowest among
Asians and African blacks and highest among whites. PD occurs throughout the world
in all ethnic groups and affects both sexes almost equally 
6
. An overall estimated annu-
al incidence of PD is 12 cases per 100.000 
23
.
V Etiology and pathophysiology
PD is characterised by the progressive death of selected heterogeneous populations of
neurons, including dopaminergic neurons in the substantia nigra pars compacta
(SNpc) 
6
. The loss of dopamine-containing neurons in PD affects different parts of the
nigral complex to different degrees, the most severe loss occurring in the ventrolate-
ral part of the SNpc 
25
. Nigrostriatal degeneration leads to (severe) dopamine deficit in
the striatum, and this process follows two regular characteristic inter- and subregio-
nal patterns: first the putamen loses considerably more dopamine than the caudate,
and within the putamen the caudal portions are more depleted of dopamine than the
rostral portions. In the caudate this rostrocaudal gradient goes in the opposite direc-
tion
26
. It is estimated that at least 30-50 % of nigral cell loss has occurred at the onset of
PD symptomatology 
6
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Being a widespread degenerative illness, PD affects the central, peripheral, and enteric
nervous systems. Components of the limbic system and the motor system have been
shown to be particularly vulnerable to severe destruction. This damage is consistently
accompanied by extranigral alterations, with predilection sites includes the entorhinal
region, the second sector of the Ammon’s horn, and important subnuclei of the amyg-
dala. In addition, the nucleus of the stria terminalis, components of the hypothalamus,
all of the non-thalamic nuclei with diffuse projections to the cerebral cortex, and most
of the centers regulating autonomic functions exhibit severe lesions. Afflicted neurons
eventually produce Lewy bodies (neuronal cell bodies, the histological hallmark of
PD) in their perikarya and Lewy neurites in their neuronal processes 
27
.
The precise mechanisms responsible for progressive cell death in PD are largely
unknown. Several mechanisms have been proposed, including oxidative stress and
free radical damage, mitochondrial (complex I) deficiency, glutamate excitotoxicity
and inflammatory responses 
6;22;23
. Cells may die by necrosis, involving the disintegra-
tion of a cell and its organelles and subsequent removal by phagocytosis 
22
. Increasing,
but controversial, evidence suggests that neuronal death may result from apoptosis,
characterised by chromatin condensation, DNA fragmentation and cell shrinkage
without an inflammatory response, which may be programmed or occurs in response
to a toxic stimulus 
23
. Further research into the etiology of PD is likely going to show
that multiple environmental and genetic factors are involved, and that PD results from
the combined effect of environmental exposure, genetic susceptibility and complex
genetic-environmental interactions 
23
. Most epidemiological studies support the role of
pesticide exposure in PD, whereby rural living, drinking well water and farming acti-
vity may be compound risk factors. Also an inverse relationship between smoking and
the risk of PD is suggested, although such an association is not confirmed in all stu-
dies 
23
. Finally, there is increasing evidence for a genetic component in the cause of PD,
and the recent identification of several genes and additional loci associated with inhe-
rited forms of PD suggest that genetic factors can influence the susceptibility to the di-
sease 
28;29
. By now at least 8 defined genetic loci are associated with autosomal domi-
nant or recessive, familiar, PD, wherein thus far 5 causative mutations have been iden-
tified
30
. The first protein implicated in familial PD was α-synuclein, a brain protein of
unknown function 
31
. Since α-synuclein aggregates in Lewy bodies, and these inclusion
bodies are present in sporadic and familial PD, this protein may play a substantial role
in both genetic and sporadic forms of the disease. However, mutations in the gene
encoding α-synuclein (which is localised on chromosome 4q21) are a very rare cause
of sporadic PD. Finally these findings have led to a general hypothesis that the patho-
genesis of PD involves the abnormal folding, aggregation and deposition of α-synucle-
in as key steps in mediating neuronal dysfunction and degeneration 
32
. 
VI The basal ganglia: a pathophysiologic PD model
The basal ganglia (striatum, pallidum, subthalamic nucleus and substantia nigra) are
crucial to function in the motor and cognitive domains, and are usually regarded as
Chapter 1
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9components of several largely segregated basal ganglia-thalamo-cortical circuits ser-
ving motor, oculomotor and cognitive functions 
33
. In models of basal ganglia function
in PD (see figure 1), loss of dopamine leads to a shift of balance within these circuits:
in the “motor circuit” modulation via dopamine D1 and D2 receptors within the stria-
tum (putamen) leads to overactivity of the subthalamic nucleus (STN) and finally
results in decreased activity of thalamocortical projection neurons 
34
. It is postulated
that this results in decreased facilitation of cortical motor areas and subsequent deve-
lopment of akinesia and bradykinesia in PD. However, these models do not account
for a variety of anatomical, physiological, experimental and clinical findings 
35
.
Figure 1 Influence of dopamine on striatal output pathways 
General introduction and aims of the thesis
Acb = nucleus accumbens; Caud = nucleus caudatus; GPe = external pallidum; GPi = internal pallidum; MC
= primary motor cortex; MD = nucleus mediodorsalis; MEA = midbrain extrapyramidal area; O = occipital
cortex; P = parietal cortex; PFC = prefrontal cortex; Put = putamen; sc = sulcus centralis; SNC = substantia
nigra pars compacta; SNR = substantia nigra pars reticulata; STN = nucleus subthalamicus; T = temporal cor-
tex; VA = nucleus ventralis anterior; VL = nucleus ventralis lateralis; VP = ventral pallidum; VTA = ventral
tegmental area 
From: Groenewegen HJ. Bewegingsstoornissen. Wolters EC, van Laar T (eds.). VU Uitgeverij, Amsterdam, 2002. By
permission of VU Uitgeverij.
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B Treatment of M. Parkinson
I Introduction
Current strategies on treatment of PD are basically focussed on control of motor symp-
toms of the disease and prevention or treatment of the complications of symptomatic
agents. Symptomatic treatment of PD mainly includes replacement or mimicking of
dopamine (dopaminergic therapy) and functional (stereotactic) neurosurgery
36
.
However, since PD progresses over time a major therapeutic aim nowadays is the li-
miting or halting of the disease process
37
. Neuroprotective therapies in PD can be
defined as those medical or surgical interventions that favourable alter the underlying
etiology or pathogenesis and thus delay the onset or slow dopaminergic decline
38
.
Neuroregeneration, the salvage of dying dopaminergic neurons, may be part of the
process of neuroprotection. Finally, neurorestauration is the process of increasing the





Current drug therapy in PD is symptomatic and primarily aimed at restoring
dopaminergic function in the striatum 
39
. Levodopa, in combination with a peripheral
decarboxylase inhibitor, is the single most effective drug for the symptomatic treat-
ment of PD 
40
and its use is associated with decreased morbidity and mortality 
41
.
Levodopa is most successful during the first years of treatment, and this period is
known as the levodopa “honeymoon” 
42
. Although usually well tolerated initially, the
chronic administration of oral levodopa is often associated with significant motor com-
plications like response fluctuations
43
. Major subtypes of these fluctuations include
“wearing off”  (shrinkage of duration of levodopa dose-induced benefit), “on-off “
(sudden, unpredictable loss of levodopa effect) and “on-dyskinesia”  (chorea at peak
dose of dopamine concentration) 
44
. The prevalence of these motor features increases
with the duration of exposure to levodopa, occurring in approximately 50 % of PD
patients who received levodopa for more than 5 years.  It is believed that these motor
phenomena may be caused by a complex combination of central pharmacodynamic
(loss of dopamine storage sites as PD progresses) and peripheral pharmacokinetic
(delayed absorption of levodopa in the duodenum and pulsatile levodopa administra-
tions) mechanisms 
45
.  Prescribing controlled-release levodopa has shown to be associ-
ated with a lower incidence of motor fluctuations and dyskinesia 
46
. Despite major
advantages, levodopa has no impact on several motor features, including speech, gait,
posture and balance, and tends to aggravate non motor features like hallucinations,
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Dopamine agonists exert their antiparkinsonian effects by acting directly on postsy-
naptic dopamine receptors and mimic the endogenous neurotransmitter
39
.
Apomorphine was the first dopaminergic agonist synthesised in the 19th century, and
in 1951 Schwab noted that apomorphine injections caused marked improvement in PD
patients 
5
. In 1974 Calne et al. reported the beneficial effects of bromocriptine, an ergot
derivate, as add-on therapy to levodopa in PD 
47
, and in 1982 pergolide, also an ergot
derivate, proved to be effective as levodopa adjunct in PD patients with motor compli-
cations 
48
. In 1997 another 2, non ergot, dopamine agonists were introduced in Europe
as potent antiparkinsonian drugs: pramipexole and ropinirole 
49
. Nowadays dopamine
agonists are basically used as monotherapy (especially in de novo patients) 
50;51
and as
adjunct to levodopa 
52
.  For PD patients requiring initiation of symptomatic therapy,
either levodopa or a agonist can be used, although levodopa provides superior motor
benefit but seems associated with a higher risk of dyskinesia 
53
.
Despite the initial outstanding benefit, long-term levodopa and dopamine agonist
therapies do not solve all the problems faced by PD patients.  Especially in advanced
disease not all parkinsonian motor features can adequately be controlled with
dopaminergic medication 
54
. Furthermore, PD is not just a motor disorder. Dysfunction
of autonomic, cognitive and psychiatric systems frequently accompany PD and these
non motor features tend to be poorly responsive to dopaminometica or may even be
worsened by antiparkinsonian medication 
42
. 
III Surgical treatments 
History and targets
Surgical treatments as possible therapy for PD have been performed since the begin-
ning of the 20
th
century. The first neurosurgical operation for relief of parkinsonism
was performed by the Frenchman Leriche in 1912 
55
. By performing a bilateral posteri-
or rhizotomy of lower cervical radices moderate tremor suppression was achieved.
Since an unwanted but associated loss of voluntary motor function accompanied this
treatment, it soon was abandoned. After Bucy and Case in 1939 extirpated the
Brodmann’s areas 4 and 6 in a patient with posttraumatic rest and intention tremor 
56
,
neurosurgeons started to perform cortical ablations.  Meyers became the first to per-
form an operation in the basal ganglia in 1939 by extirpating the almost entire head of
the caudate nucleus in a postencephalitic parkinsonian patient 
57
.  In addition he pla-
ced lesions in other extrapyramidal structures like the pallidofugal fibers, which relie-
ved tremor and rigidity in 60 % of PD patients. The development of stereotactic instru-
ments, which already had been designed initially by Clarke and Horsley in 1906 
58
, and
stereotaxis atlases, first introduced by Spiegel and Wycis in 1952 
59
, permitted more
accurate target localisation and fewer side effects and subsequently the application for
stereotactic surgery increased. Were initially the inner segment of the globus pallidus
12
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and the ansa lenticularis the main targets for surgery, several groups (e.g. Leksell) pre-
ferred attacking the posteroventral pallidum 
60
.  Since Cooper in 1958 noted that lesi-
ons placed within the thalamus provided similar effects and less side effects, thalamo-




With the introduction of levodopa in 1969 the demand for surgery declined.  In the
1970s and 1980s surgical procedures were rarely performed, but because of insufficient
relief of tremor by levodopa, thalamotomy regained popularity as surgical target 
62
.
Advancements in understanding of the pathophysiology of PD, based on models of
basal ganglia function 
63
, led to renewed surgical procedures in the 1990s. In 1992
Laitinen described 38 PD patients in whom he had performed a lesion of the pos-
teroventral region of the internal part of the pallidum (GPi), following the original con-
cept of Leksell 
64
. Based on these results several groups began to perform posteroven-
tral GPi pallidotomy in PD 
65;66
. The most consisted finding in these studies has been
the dramatic improvement in contralateral dyskinesia, while results with respect to
parkinsonism were less striking. In addition, side-effects of bilateral pallidotomy
largely restricted surgery to unilateral procedures 
67
, and long term results of pallido-
tomy on persistent benefit are variable 
68
.
Deep Brain Stimulation (DBS), introduced by Heath et al in 1950 
69
, was based on the
common effect of tremor suppression during high-frequency testing of the target site
during ablative surgery with the electrode to confirm proper placement. DBS as a
treatment for PD was introduced by Benabid et al in 1987 
70
and was first tested in the
ventral intermediate (VIM) nucleus of the thalamus in patients with tremor dominant
disease 
71
. Although DBS of the VIM has now been shown to dramatically ameliorate
contralateral tremor 
72
, most studies have not found significant benefit in other PD
symptoms. The major advantages to DBS is that, unlike ablative surgery, it permits a
bilateral procedure, its side-effects associated with stimulation are reversible, and
adjustment of stimulation parameters maximises benefits and minimises adverse
events 
73
. Because clinical efficacy of thalamus-DBS in PD was limited to tremor sup-
pression only, interest in the late 1990s shifted to DBS of the GPi and the subthalamic
nucleus (STN). Based on extensive electrophysiological and metabolic studies indica-
ting overactivity of GPi and STN in animal PD models and PD patients 
74;75
, DBS of
these structures offered an opportunity to functionally inhibit their overactivity with-
out making a destructive lesion. In addition, high-frequent stimulation of the STN in
an animal model of PD, the MPTP-lesioned monkey, decreased tremor, rigidity and
akinesia successfully. Since then several studies on bilateral GPi-DBS showed allevia-
tion of all PD motor symptomatology 
76;77
. Limousin et al (1995) were the first to
describe the beneficial efficacy of STN-DBS in 3 PD patients with advanced disease 
78
.
Like GPi-DBS, STN-DBS improved all cardinal motor features of PD, but no ran-
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By now, the precise mechanism as to how DBS exactly works is not known 
73
. It is
believed that DBS suppresses the neuronal firing pattern in the target area either
directly or by inducing the release of inhibitory transmitters; other possibilities include
back firing, “jamming” and depolarisaton blockade 
80
. 
Chronic stimulation of the subthalamic nucleus
A. The subthalamic nucleus
The subthalamic nucleus (STN) was “discovered” by the French investigator Jules
Bernard Luys 
81
, and subsequently he published his knowledge in his book “Studies on
the structure, functions and diseases of the nervous sytem” in 1865. The STN is a small
biconvex-shaped structure surrounded by dense bundles of myelinated fibers (see fi-
gure 2). Its anterior and lateral borders are adjacent to the internal capsule and rostro-
medially the STN lies adjacent to the Fields of Forel. Posteromedial it is adjacent to the
red nucleus and its ventral limits are the cerebral peduncle and the ventrolateral sub-
stantia nigra 
82
. Dorsally the STN is limited by the fasciculus lenticularis and zona
incerta. The volume of the STN is approximately 175 mm
3
in humans (Levesque, 2005).
Figure 2 Coronal brain section representing the major anatomical structures and fibre tracts
associated with the subthalamic nucleus
AL = ansa lenticularis; CP = cerebral peduncle; FF = Fields of Forel; GPe = globus pallidus externus; GPi =
globus pallidus internus; H1 = H1 Field of Forel (thalamic fasciculus); IC = internal capsule; LF = lenticular
fasciculus (H2); PPN = pedunculopontine nucleus; Put = putamen; SN = substantia nigra; STN = subthala-
mic nucleus; Thal = thalamus; ZI = zona incerta.
From: Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM. The subthalamic nucleus in the context of movement
disorders. Brain 2004;127:4-20. By permission of Oxford University Press.
Functionally the STN is subdivided into a limbic and associative part (the medial por-
tion of the rostral two-thirds) and a portion related to motor circuits (dorsal part of the
lateral portion of the rostral two-thirds) within the basal ganglia 
83
. Most of the cortical
afferents to the STN arise from the primary motor cortex, (pre-) supplementary motor
area and the dorsal and ventral pre-motor cortices and predominately innervate the
dorsal part. The ventromedial portion of the STN receives afferents from the frontal
eye field (area 8) and the supplementary frontal eye field 
82
.  However, its major affe-
rents comprises the projection from the external pallidum, and, to a lesser extent, tha-
lamus (parafascicular and centromedian nuclei) and brainstem (substantia nigra,
pedunculopontine nucleus, tegmental nuclei, dorsal raphe nucleus). The major effe-
rent projections from the STN are mainly directed to both segments of the globus pal-
lidus, substantia nigra and striatum. The STN innervates both components of the sub-
stantia nigra: although most fibers innervate the SNpr, some ascend and reach the
SNpc, comprising one mechanism responsible for the regulation of dopamine release
84
.
The main excitatory drive to the STN is provided by excitatory amino acids, and
NMDA and AMPA receptors have been described in STN neurons 
85
.  It is believed that
these multiple glutamate receptor subtypes mediate a complex signalling pathway in
the STN 
86
.  GABAergic activity also has a major role in aspects of STN physiology by
modulating its firing rate and pattern of neuronal activity. The impact of GABA on the
STN is related to the initial membrane potential of the cells, which is strongly dictated
by pallidal afferents 
86
. It is estimated that in vivo 55-65 % of the STN neurons fire irre-
gularly, whereas 15-25 % fire regularly and 15-50 % present bursting activity in non-
human primates, and the average firing rate of STN neurons is 18-25 Hz 
87;88
. 30-50 %
of STN neurons are related to movement, and most of them are localised in the dorsal
half of the nucleus and are activated by passive or active movement of contralateral
joints 
87
. In addition, 20 % of the neurons are responsive to eye fixation or visual sti-
muli, and these are primarily found in the ventral STN 
89
. The STN is currently thought
to play a prominent role in the pathophysiology of PD 
63
. Metabolic, electrophysiolo-
gical and behavioural studies performed mainly in the MPTP monkey model of PD
revealed an increase in neuronal activity of the STN and its main output basal ganglia
nuclei. In the current model of the basal ganglia in PD, STN hyperactivity has been
attributed to the underactivation of the globus pallidus externus (GPe) due to abnor-
malities in the indirect pathway elicited by dopamine depletion in the striatum.
However, recent studies suggest that other brain regions, e.g. the cerebral cortex and
thalamus, may also be responsible for increased STN activity in PD 
90
. The pathologi-
cal STN drive thereby modifies the overall activity in output structures like SNr, GPi,
GPe and PPN, and disrupts the normal physiology of the basal ganglia. In the SNpc,
STN glutamatergic overactivity is predicted to enhance bursting activity and increa-
ses the release of dopamine. Although this has been considered an initial compensa-
tory mechanism after dopamine depletion, this excessive glutamate release may lead
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B. Chronic bilateral STN-DBS
Limousin et al were the first to describe the clinical efficacy of bilateral STN-DBS in 3
advanced PD patients, suffering from unpredictable motor fluctuations 
78
.  At 3 months
follow up, the UPDRS motor subscore (part III) in off-medication condition had
improved by 84 %, 75 % and 42 % respectively. The individual levodopa dosage could
be reduced by 50 % and 40 % in the first 2 patients, and was withdrawn in the third in
the following months postoperatively. They subsequently extended their data set and
in 1998 published the results of bilateral STN-DBS in 24 patients with advanced PD,
suffering from disabling motor fluctuations 
92
. After 1 year of STN-DBS the motor
scores (as examined by the UPDRS part III in off- medication condition) improved by
60 %, including subscores on akinesia, tremor, rigidity and gait. The mean dosage of
dopaminergic drugs was reduced by half, and, consequently, levodopa induced dys-
kinesia significantly diminished. On average, neuropsychological assessment showed
no change after surgery, despite worsening of cognitive impairment in 1 patient. The
most serious adverse event was an intracerebral hematoma (1 patient) and a subcuta-
neous infection developed at the site of the extension lead in 1 patient. In 8 patients
transient adverse effects on mental status (hallucinations, confusion) developed after
surgery, which lasted for a maximum of 2 weeks.
Since then several institutions published their beneficial results on bilateral STN-DBS
in PD, of which the main results are emphasised in table 2.
It can be concluded that bilateral STN-DBS substantially improves all levodopa
responsive PD motor features significantly 
93
up to (at least) 5 years after surgery 
94
.
Since STN-DBS mimicks the effect of levodopa 
95
, it allows dopaminergic therapy to be
(partially) discontinued postsurgically. All studies have shown a significant improve-
ment of time spent with disabling dyskinesia or diminishing of severity of dyskinesia
93
.
In addition, the improvement in on-period dyskinesia might be mainly due to this
decrease in levodopa daily dose 
96
, although a specific effect of stimulation on motor
fluctuations itself is also argued 
93
. Since DBS is an elective procedure, the disability of
the patient must be profound to justify the risk of surgery (permanent morbidity and
mortality of STN-DBS: 1-3 %) 
93
. Most important side effects of the STN-DBS procedure
are mild and transient, and consist of direct surgical complications (e.g. asymptomatic
intracerebral bleeding detected on MRI, wound healing problems) or postoperative
confusion 
94
. Persistent body weight gain has consistenly been reported after STN-
DBS
97





. The latter is probably caused by direct stimulation effects of DBS on
the STN or its adjacent structures, which have strong connections with limbic struc-
tures 
102
. As a result, demented patients and patients suffering from depression or le-
vodopa-induced psychosis are considered not to be suitable candidates for STN-DBS,





Finally, there is much debate about as to how STN-DBS exerts its efficacy. The imme-
diate reduction of patients’ rigor and rest tremor is believed to result from a depola-
rization block of the neurons surrounding the electrode tip or from a disruption of
pathologically synchronised neural firing pattern by additional high-frequent stimuli
(neural jamming)
80
. In contrast, the amelioration of akinesia and the induction of dys-
kinesia by STN-DBS takes minutes up to hours or even weeks to occur. This observa-
tion, as well as the clinicial experience that motor improvement achieved by STN-DBS
resembles those achieved after levodopa, raised questions about a delayed increase of
striatal dopaminergic transmission following DBS. In addition, the area encompassing
the dorsal STN and the axons dorsal to the STN seems the most effective target for the
amelioration of PD symptoms after successful STN-DBS 
103
. Since the nigrostriatal tract




Limousin (1998), Grenoble 24 12 60 50
Moro (1999), Rome 7 16 42 65
Kleiner (1999), Toronto 25 24 48 38
Houeto (2000), Paris 23 6 67 61
Rodriquez (2000), Pamplona 15 12 74 55
Molinuevo (2000), Barcelona 15 6 66 80
Volkmann (2001), Düsseldorf 16 12 60 65
Obeso (2001), multi center 96 3 49 47
Vingerhoets (2002), Lausanne 20 21 45 79
Østergaard (2002), Aarhus 26 12 64 22
Thobois (2002), Lyon 18 6 55 66
Herzog (2003), Kiel 48 6 51 49
Krack (2003), Grenoble 49 60 54 63
Esselink (2004), Amsterdam 34 6 59 33
Ford (2004), New York 30 12 29.5 30
* in months
# reduction in % (in off- medication on-stimulation condition) of pre-operative score
+ reduction in % of pre-operative dopaminergic therapy
Table 2 The efficacy of STN-DBS in PD
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runs in close apposition to this dorsal surface of the STN, it also is subject to the effects
of DBS. It is hypothized that one possible effect of DBS could be the activation of those
nigrostriatal axons arising from the SNpc, with the release of endogenous dopamine
in the striatum 
104
. However, recent Positron Emission Studies successively failed to
show a substantial increase of striatal dopamine release after STN-DBS in PD 
104-106
.  
IV Neuroprotective, neurorestaurative and neuroregenerative therapy 
In the absence of an identified biological marker in sporadic PD, prevention of dopa-
minergic cell decline is aimed at slowing, stopping or reversing neuronal death 
37
. It is
obvious that any neuroprotective therapy for PD should ideally be introduced before
the onset of clinical manifestation, or at least as soon as possible when clinical features
of PD become manifest.
The first drugs to be studied in PD were antioxidants. In 1993 the DATATOP study
evaluated the antioxidant vitamin E and the MAO-B inhibitor deprenyl as putative
neuroprotective therapy in PD 
107
. While no beneficial effect of vitamin E was detected,
deprenyl seemed to slow disease progression. However, since deprenyl also exerted
symptomatic efficacy, interpretation of the study results seemed confounded; subse-
quently, an additional study on deprenyl versus placebo showed confounding results
too
108
.  In a double-blind placebo-controlled pilot study coenzyme Q10 (an enhancer of
ATP production and antioxidant) was studied as a putative neuroprotective agent in
PD in 2002 
109
. Although a reduced rate of deterioration of patients’ motor function du-
ring the study course was noticed, again an unexpected symptomatic effect of the drug
confounded study interpretation. Dopamine agonists also exhibit neuroprotective
potency as antioxidants, and in addition decrease dopamine turnover and thereby
reduce the generation of free radicals. In laboratory studies dopamine agonists pro-
tected dopaminergic and nondopaminergic neurons from toxins in PD models 
110
.
Thus far 2 neuroimaging studies (CALM-PD and REAL-PET) on 2 dopamine agonists
(pramipexole and ropinirole) have been performed testing the capacity of these ago-
nists to modify disease progression in PD 
111;112
. Both studies demonstrated that
dopamine agonists were associated with a significant delay in the rate of tracer uptake
decline, but, however, neither study showed a corresponding clinical benefit. Also
pharmacological differences in the capacity of these drugs to regulate neuroimaging
tracer dynamics have made the interpretation of study results controversial 
113
.
The first promising attempt to treat PD patients by use of cell transplantation in 1985
involved striatal infusion of autologous adrenal medullary cells 
114
. However, later stu-
dies showed poor results with no improvement in patients’ motor disability 
115;116
.
Following several unblinded but promising case series of human foetal cell transplan-
tation, in 2001 Freed published results on fetal nigral cell transplantation versus sham
surgery in 40 PD patients 
117
. Again, no significant improvement was established,
although younger patients showed a small benefit. A double-blind controlled trial of
18
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bilateral fetal nigral transplantation in PD by Olanow 
118
in 2003 showed similar disap-
pointing results. A small, unblinded study using xenogenic neural transplants of
embryonic porcine ventral mesencephalic cells in PD showed small motor benefit in
study patients 
119
. Controlled trials with larger graft doses are needed to assess this pro-
cedure’s efficacy in the future. Studies on embryonic-stem-cell transplantation are in
the early stages of development.
The use of neural trophic factors has been proposed as a method of promoting the
restauration and maintenance of degenerating dopaminergic cells. A large double-
blind, placebo controlled trial of intraventricular infusion of glial-cell-derived neu-
rotrophic factor showed no benefit at 8 months follow-up 
120
. However, since autopsy
results suggested that the neurotrophic factor had not reached the target area in this
study, direct infusion of glial-cell derived neurotrophic factor into the putamen
showed indeed a modest motor benefit in patients in another study 
121
. Recently a ran-
domised, double blind, placebo-controlled phase II study has been stopped because of
lack of efficacy (Amgen Inc., 2004).
C STN-mediated excitotoxicity in PD: a target for neuroprotection
I Introduction
Essential to the concept that the STN might contribute to neurodegeneration in PD is
the existence of a glutamatergic pathway between the STN and the SNpc. Anatomical
studies clearly demonstrated these glutamatergic projection in several animal models
of PD 
122
. In addition, electrophysiologic studies confirm that the STN exerts an excita-
tory effect on dopamine neurons in the SNpc, which is mediated by glutamate acting
on NMDA receptors 
123
. Theoretically, increased STN activity in PD may result from
reduced inhibition, increased excitation or both.  It is believed that a loss of inhibitory
drive of the external pallidum (GPe), secondary to dopamine depletion, to the STN is
the major mechanism responsible for excess firing of the STN in PD 
124
. Because STN
neurons use glutamate as a neurotransmitter, there is reason for concern that excess
neuronal firing in the STN might lead to excitotoxic damage in its target structures,
especially the SNpc. Although the precise molecular mechanisms involved in this pro-
ces are unresolved, excitotoxicity primarily involves an NMDA-mediated rise in in-
tracellular Ca
2+ 125
. In normal neurons there is an ATP-dependent Mg
2+
blockade of
NMDA channels. As a result, physiologic concentrations of glutamate do not excessi-
vely activate NMDA receptors or promote calcium influx. However, in PD the release
of high concentrations of glutamate could overcome this blockade and stimulate
NMDA receptors inducing an alteration in calcium influx. In addition, a bioenergetic
cellular defect due to primary mitochondrial (complex I) dysfunction 
126
in PD results
in a loss of  the voltage dependant Mg blockade of  NMDA receptors and permits even
physiologic concentrations of glutamate to induce excitotoxicity 
127
. Finally, lesions of
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the STN have shown to be neuroprotective in several experimental models of PD.
Piallet et al (1996) showed that chemical ablation of the STN prevented dopaminergic
nigral degeneration in 6-OHDA lesioned rats 
128
. In their study the number of tyrosine
hydroxylase-immunoreactive cells in the SNpc was not significantly different on the
STN-lesioned side compared to the control side. In 1999, Nakao et al showed an atte-
nuated progressive loss of nigral TH-positive neurons after chemical STN ablation in
3- nitropropionic lesioned rats 
129
.  
II The excitotoxic hypothesis in PD
Rodriquez et al speculated that the STN plays a major role in the pathogenesis of PD
according to the following sequence of events 
124
:
1. An inherited or acquired mitochondrial defect and / or oxidant stress make 
dopaminergic SNpc neurons susceptible to noxious stimuli and vulnerable to 
degeneration or even apoptosis; as a result a small portion of these cell actually 
degenerate
2. The loss of dopaminergic neurons causes a reduction in striatal dopamine, which 
results in a reduced dopaminergic inhibition of D2 striatal neurons, increased inhi-
bition of the GPe, and finally disinhibition of the STN, with increased activity in 
excitatory STN neurons
3. Enhanced STN neuronal firing produces excessive glutamate release in the SNpc
4. Increased glutamate release in the SNpc leads to a further loss of dopaminergic 
neurons and reduction in striatal dopamine
5. Increased degeneration of SNpc neurons and dopamine depletion induces further
disinhibition of the STN
6. Finally, a vicious cycle is created in which dopamine neuronal degeneration in the
SNpc leads to further STN disinhibition, and STN overactivity leads to excitotoxic
damage in remaining SNpc neurons
7. When degeneration of SNpc neurons and loss of striatal dopamine reach a critical
level, the signs and symptoms of PD emerge
This hypothetic model illustrates how disinhibition of the STN and resultant exci-
totoxicity could contribute to the neurodegenerative process in PD, regardless of
the specific, and yet unknown, etiology. A consequence of this hypothesis is the aim
of providing a neuroprotective therapy in PD that slows the rate of disease progres-
sion by reducing STN overactivity. Since it is estimated that approximately 30-50 %
of dopamine neurons already have degenerated by the time the first signs and
symptoms of PD appear 
130
, any “protective” treatment should be introduced as
early as possible in the course of the disease. Theoretically, such a treatment could
involve dopamine agonists (by restoring dopaminergic tone), agents that inhibit
glutamate release, selective NMDA receptor antagonists (to block glutamate
release) and surgical interventions that inhibit neuronal firing of the STN. 
20
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Since all pharmacological therapies thus far have failed to show a neuroprotective
effect in PD in vivo, surgical treatments that inhibit STN firing represent an addi-
tional and promising option to attenuate progressive dopaminergic cell decline. In
addition, the clinical introduction of DBS of the STN in PD has yet provided an
opportunity to functionally inhibit the STN.
D FDOPA-PET and M. Parkinson
I Positron Emission Tomography
Positron Emission Tomography (PET) is an imaging method used to track the regio-
nal distribution and kinetics of chemical compounds labelled with short-lived-
positron-emitting isotopes in the living body 
131
. Positron imaging was initially sug-
gested by Wrenn et al in 1951 
132
. At that time, cyclotrons became available for the pro-





N) and fluorine-18 (
18
F) were performed. PET studies are carried out by admini-
stering a tracer labelled with a positron-emitting isotope with a short half-life genera-
ted by a cyclotron. The tomographic image in PET is formed by recording of two 511
keV photons emitted in positron decay with a circumferential array of radiation detec-
tors. Since these photons are simultaneously emitted 180
0
apart, a special coincidence
technique is used to define the origin of emission. These data are processed through a
conventional reconstruction algorithm to form the tomographic images of the tracer
concentration in tissue. While the first PET scanner (PETT II) provided a single tomo-
graphic image plane with restricted spatial resolution, modern scanners have multiple
rings of detectors to allow the simultaneous collection of multiple planes of imaging
133
.
In addition to conventional datasets of regional tracer uptake collected in two-dimen-
sional (2-D) mode, nowadays software is available allowing PET data to be acquired in
a 3-D mode, which have led to a further increase in spatial resolution 
134
. 
The integrity of the presynaptic nigrostriatal dopaminergic projection can be studied
in vivo with radiotracers whose striatal uptake reflects a measure of structural as well
as the biochemical integrity of the dopaminergic nerve terminals (FDOPA) or
dopamine transporter density (FP-CIT, β-CIT) 135.
II FDOPA-PET
PET was the first technology that enabled direct measurement of components of the
dopamine system in the living human brain 
131
. In 1983 Garnett et al reported on the
successful application of 6-[
18
F]fluoro-L-3, 4-dihydroxyphenylalanine (FDOPA) for
PET studies of nigrostriatal dopaminergic neurons in living man
136
, while in 1986
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Since then FDOPA-PET has provided an objective means of assessing the functional
integrity of the presynaptic nigrostriatal dopaminergic projections in vivo 
138
. It esti-
mates the rate of enzymatic decarboxylation of FDOPA to 
18
F-dopamine as well as its
storage in dopaminergic nerve terminals. Although striatal FDOPA uptake is not a
measurement of endogenous dopamine synthesis, it is highly correlated with
dopamine cell counts measured in post mortem specimens 
139
. FDOPA-PET can sensi-
tively discriminate PD from normal populations, and several studies reported a
marked decrement of striatal FDOPA uptake in PD, which is specifically more pro-
nounced in the putamen than in the caudate 
20;140
. Various studies have demonstrated
that specific FDOPA uptake in the putamen of PD patients is on average 40 % of con-
trol values and in caudate 60 % 
141
.  In early PD these values can be considerably high-
er and for caudate will often be normal. At very late stages of the disease a 60-70 % or
more drop in striatal uptake in PD may be observed, caudate being less severely affec-
ted than putamen with however a significant uptake decrement in advanced stages of
the disease. Initially, FDOPA-PET has also been used to differentiate among parkin-
sonian syndromes (e.g. Multi System Atrophy, Progressive Supranuclear Palsy).
Subsequent studies have shown that differences on the presynaptic dopaminergic
level are not sufficiently precise to categorise individual cases of disease 
138
.
III FDOPA-PET studies on the rate of PD progression 
FDOPA-PET provides a potential means of objectively monitoring disease progression
in PD. The first reported PET study was by Bhatt (1991) who measured striatal FDOPA
uptake on 2 occasions over 3 years in groups of 9 PD patients and 7 normal subjects 
142
.
The mean interval between the scans was 3.3 years for the group with idiopathic
parkinsonism and 3.9 years for the control subjects. Both groups showed a statistical-
ly significant 5 % reduction of striatal FDOPA uptake over the study interval and the
rate of decrease was almost identical in each group. They inferred that the usual rate
of loss of integrity of the dopaminergic nigrostriatal pathway in PD patients was slow
and the rate of change between the two groups was comparable. A follow-up study
was performed by Vingerhoets et al 
143
. They performed FDOPA-PET on two occasions,
7 years apart, on 16 patients with PD (mean age 51 years, mean disease duration 4.5
years) and 10 normal controls (mean age 54 years). Their PET index ((striatal-occipi-
tal)/occipital ratio) dropped by 1.7 % per year versus the normals’ ratio 0.3 %, and in
addition the ratios in the PD group progressed significantly faster than the controls.
However, one problem with the interpretation of study results was that large whole
striatal Regions Of Interest were employed to analyse disease progression whereas the
PD pathology primarily targets dopamine storage in the putamen only. 
Morrish et al, using an FDOPA influx constant (Ki), studied PD disease progression in
a group of 10 patients with recent onset PD (mean age 53.7 years, mean disease dura-
tion 18 months), and a group of seven patients with established PD (mean age 60 years,
22
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mean disease duration 71 months), using both clinical assessment and FDOPA-PET 
144
.
Results were compared with those of a group of 10 normal subjects (mean age 66
years). The mean annual rate of reduction in mean putamen Ki in the PD patients was
12.5% per annum, whereas the control group showed no significant change in Ki over
a mean of 32 months follow up. The rate of progression was more rapid in the recent
onset compared with the established disease group but this did not reach statistical
significance. Assuming a linear progression for the entire group they additionally esti-
mated PD symptom onset with a mean preclinical period of 3.1 years. They successive-
ly extended their study in 1998 on 32 PD patients with PD (mean age 58 years, mean
disease duration 39 months) using graphical (Ki) and ratio methods of analysis 
145
. The
mean annual rate of deterioration in specific putamen FDOPA uptake was 9 % from
baseline scan (or 4.7% of normal mean). Extrapolation of these data suggested that
symptom onset occurred after a 30 % loss of dopaminergic terminal function and the
estimated preclinical window was estimated to be 6 ± 3 years.  
Finally, in 2001 Nurmi et al investigated the rate of progression in PD using FDOPA-
PET in 21 PD patients 
146
. FDOPA-PET was carried out twice at an approximately 5-
year interval. The FDOPA uptake declined by the time of the second PET scan and the
calculated annual rate of decline was 8.3 % of the baseline mean in the anterior puta-
men, and 10.3 % in the posterior putamen. In the caudate nucleus, FDOPA uptake
decreased by 5.9  % of the baseline mean per year. They successively estimated the pre-
clinical PD period being longest for the posterior putamen (6.5 years). In healthy con-
trols no significant decline in FDOPA uptake in any striatal subregion was established.
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Aims of the thesis
Since glutamate-mediated excitotoxicity is suggested to contribute to nigrostriatal
degeneration in PD, the clinical introduction of STN-DBS in PD provided an opportu-
nity to functionally inhibit STN activity and therefore decrease disease progression. 
The primary aim of this thesis was to prospectively determine disease progression in
a population of PD patients after STN-DBS by means of repetitive FDOPA-PET. Is
STN-DBS really “neuroprotective” in PD?
In addition, we studied the clinical efficacy of STN-DBS on motor features in PD. Does
STN-DBS “work” in our own PD study population?
We also investigated the nature of the relationship between striatal dopamine deple-
tion and cognitive functioning in PD. Does FDOPA-PET reveal the nature of basal gan-
glia dysfunction in patients’ cognitive impairment?
Finally, we sought to determine the predictive value of the patients’ presurgical nigro-
striatal status on motor efficacy of STN-DBS in PD using FDOPA-PET. Is the nigrostri-




1. Roberts S. James Parkinson. From Apothecary to General Practitioner. London, Royal Society of
Medicine Press Ltd., 1997.
2. Parkinson, J. An essay on the shaking palsy. London, Whittingham and Rowland, 1817. 
3. Wilkins, R. H. and Brody, I. A. Parkinson’s Syndrome.  87-92. 1997. Illinois, The American
Association of Neurological Surgeons. Neurological classics. 
4. Olanow CW, Perl DP, DeMartino GN, McNaught KSP. Lewy-body formation is an aggresome-
related process: a hypothesis. Lancet Neurology 2004;3:496-503.
5. Tolosa E, Marti MJ, Valldeoriola F, Molinuevo JL. History of levodopa and dopamine agonists in
Parkinson’s disease treatment. Neurology 1998;50:S2-10.
6. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998;339:1044-53.
7. Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson’s di-
sease. Parkinson Study Group. Arch Neurol 2000;57:369-72.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s
disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
9. Horstink MW, Morrish PK. Preclinical diagnosis of Parkinson’s disease. Adv Neurol 1999;80:327-
33.
10. Tissingh G, Berendse HW, Bergmans P, DeWaard R, Drukarch B, Stoof JC et al. Loss of olfaction
in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov Disord
2001;16:41-6.
11. Yamamoto M. Depression in Parkinson’s disease: its prevalence, diagnosis, and neurochemical
background. J Neurol 2001;248 (Suppl 3):III5-11.
12. Jost WH, Braune S. Autonomic dysregulation in patients with idopathic Parkinson’s disease.
Aktuelle Neurologie 2001;28:S235-S241.
13. Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. J Neurol 1997;244:2-8.
14. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson’s disease. Arch Neurol 1999;56:33-9.
15. Stocchi F, Brusa L. Cognition and emotion in different stages and subtypes of Parkinson’s disease.
J Neurol 2000;247 Suppl 2:II114-II121.
16. Lachenmayer L. Differential diagnosis of parkinsonian syndromes: dynamics of time courses are
essential. J Neurol 2003;250 (Suppl 1):I11-I14.
17. Hobson DE. Clinical manifestations of Parkinson’s disease and parkinsonism. Canadian J Neurol
Sc 2003;30:S2-S9.
18. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of
Parkinson’s disease. J Neurol 2000;247 (Suppl 2):II11-II18.
25
General introduction and aims of the thesis
19. Antonini A, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C et al. Differential diagno-
sis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord 1998;13:268-74.
20. Leenders KL. Characterisation of Parkinson’s disease using positron emission tomography. In:
Dostert P, Riederer P, Strolin Benedetti M, Roncucci R (eds.). Early Markers in Parkinson’s and
Alzheimer’s Disease. Springer-Verlag 1990: 59-69.
21. de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG et al. Prevalence
of Parkinson’s disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143-6.
22. Schapira AH. Science, medicine, and the future: Parkinson’s disease. BMJ 1999;318:311-4.
23. Huang Z, Fuente-Fernandez R, Stoessl AJ. Etiology of Parkinson’s disease. Can J Neurol Sci
2003;30 (Suppl 1):S10-S18.
24. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M et al. Prevalence of
Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic
Diseases in the Elderly Research Group. Neurology 2000;54:S21-S23.
25. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns
of loss of dopamine-containing neurons in Parkinson’s disease. Brain 1999;122:1437-48.
26. Hornykiewicz O. Biochemical aspects of Parkinson’s disease. Neurology 1998;51:S2-S9.
27. Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neurol 2000;247 (Suppl 2):II3-10.
28. Gasser T. Genetics of Parkinson’s disease. J Neurol 2001;248:833-40.
29. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson’s disease.
Neurology 2002;58:179-85.
30. Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson’s disease. Nat. Rev Neurosci
2004;S58-S62.
31. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003;18:S2-S12.
32. Feany MB. New genetic insights into Parkinson’s disease. N Engl J Med 2004;351:1937-40.
33. Brown P, Marsden CD. What do the basal ganglia do? Lancet 1998;351:1801-4.
34. Wichmann T, DeLong MR. Functional and pathophysiological models of the basal ganglia. Curr
Opin Neurobiol 1996;6:751-8.
35. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N et al.
Pathophysiology of the basal ganglia in Parkinson’s disease. Trends Neurosci 2000;23:S8-19.
36. Tintner R, Jankovic J. Treatment options for Parkinson’s disease. Curr Opin Neurol 2002;15:467-76.
37. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson’s di-
sease: an evidence based assessment. Lancet 2002;359:1589-98.
26
Chapter 1
38. Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s disease.
Lancet Neurology 2004;3:466-74.
39. Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson’s disease. J Neurol
Neurosurg Psychiatry 2000;68:685-9.
40. Koller WC, Hubble JP. Levodopa Therapy in Parkinson’s Disease. Neurology 1990;40:40-7.
41. Diamond SG, Markham CH, Hoehn MM, Mcdowell FH, Muenter MD. Effect of Age at Onset on
Progression and Mortality in Parkinson’s Disease. Neurology 1989;39:1187-90.
42. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current
Parkinson’s disease therapy. Ann Neurol 2003;53 (Suppl 3):S3-12.
43. Stern MB. Contemporary approaches to the pharmacotherapeutic management of Parkinson’s di-
sease: An overview. Neurology 1997;49:S2-S9.
44. Djaldetti R, Melamed E. Management of response fluctuations: practical guidelines. Neurology
1998;51:S36-S40.
45. Djaldetti R, Melamed E. New therapies for Parkinson’s disease. J Neurol 2001;248:357-62.
46. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release car-
bidopa/levodopa in PD - A 5-year randomized multicenter study. Neurology 1999;53:1012-9.
47. Calne DB, Leigh PN, Teychenn PF, Bamji AN, Greenacr JK. Treatment of Parkinsonism with
Bromocriptine. Lancet 1974;2:1355-6.
48. Olanow CW, Alberts MJ. Double-Blind Controlled-Study of Pergolide Mesylate in the Treatment
of Parkinson’s Disease. Clin Neuropharm 1987;10:178-85.
49. Jankovic J. New and emerging therapies for Parkinson’s disease. Arch Neurol 1999;56:785-90.
50. Holloway R, Shoulson I, Kieburtz K, McDermott M, Tariot P, Kamp C et al. Pramipexole vs le-
vodopa as initial treatment for Parkinson’s disease - A randomized controlled trial. JAMA
2000;284:1931-8.
51. Barone P, Bravi D, Bermejo-Pareja F, Marconi R, Kulisevsky J, Malagu S et al. Pergolide monothe-
rapy in the treatment of early PD - A randomized, controlled study. Neurology 1999;53:573-9.
52. Poewe W. Adjuncts to levodopa therapy - Dopamine agonists. Neurology 1998;50:S23-S26.
53. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of
treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards
Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-7.
54. Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. N Engl J Med 1998;339:1130-43.
55. Speelman JD, Bosch DA. Resurgence of functional neurosurgery for Parkinson’s disease: a histo-
rical perspective. Mov Disord 1998;13:582-8.
27
General introduction and aims of the thesis
56. Bucy PC, Case TJ. Tremor, physiologic mechanism and abolition by surgical means. Arch Neurol
1939;41:721-46.
57. Meyers R. Surgical procedure for postencephalitic tremor, with notes on the physiology of the pre-
motor fibers. Arch Neurol 1940;44:455-9.
58. Clarke RH, Horsley VH. On a method of investigating the deep ganglia and tracts of the central
nervous sytem (cerebellum). BMJ 1906;2:1799-800.
59. Spiegel EA, Wycis HT. Stereoencephalotomy (thalamic related procedures) part 1. In: Methods
and Atlas of the Human Brain. New York: Grune & Stratton, 1952.
60. Svennilson E, Torvik A, Lowe R, Leksell L. Treatment of parkinsonism by stereotaxic thermole-
sions in the pallidal region. Acta Psych Scand 1960;35:358-77.
61. Cooper IS, Bravo GJ. Anterior choroidal artery occlusion, chemopallidectomy and chemothala-
motomy in parkinsonism: a consecutive series of 700 patients. In: Fields WS (ed). Pathogenesis
and Treatment of Parkinsonism, 1958: 325-63.
62. Siegfried J. Is the neurosurgical treatment of Parkinson’s disease still indicated? J Neural Trans
1980;195-8.
63. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci
1990;13:281-5.
64. Laitinen LV, Bergenheim AT, Hariz MI. Leksells Posteroventral Pallidotomy in the Treatment of
Parkinson’s Disease. J Neurosurg 1992;76:53-61.
65. Fine J, Duff J, Chen R, Chir B, Hutchison W, Lozano AM, Lang AE. Long-term follow-up of uni-
lateral pallidotomy in advanced Parkinson’s disease. N Engl J Med 2000;342:1708-14.
66. Pal PK, Samii A, Kishore A, Schulzer M, Mak E, Yardley S et al. Long term outcome of unilateral
pallidotomy: follow up of 15 patients for 3 years. J Neurol Neurosurg Psychiatry 2000;69:337-44.
67. De Bie RMA, Schuurman PR, Esselink RAJ, Bosch DA, Speelman JD. Bilateral pallidotomy in
Parkinson’s disease: A retrospective study. Mov Disord 2002;17:533-8.
68. Vitek JL, Bakay RAE, Freeman A, Evatt M, Green J, McDonald W et al. Randomized trial of palli-
dotomy versus medical therapy for Parkinson’s disease. Ann Neurology 2003;53:558-69.
69. Heath RG. Electrical Self-Stimulation of Brain in Man. Am J Psychiatry 1963;120:571-577.
70. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and sti-
mulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson’s disease. Appl
Neurophysiol 1987;50:344.
71. Benabid AL, Pollak P, Gervason C, Hoffmann D, Gao DM, Hommel M et al. Long-term suppres-
sion of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet
1991;337:403-6.
72. Koller W, Pahwa R, Busenbark K, Hubble J, Wilkinson S, Lang A et al. High-frequency unilateral




73. Olanow CW, Brin MF. Surgical therapies for Parkinson’s disease - A physician’s perspective. In:
Advances in Neurology 86. Parkinson’s Disease. Lippincott Williams & Williams. Philadelphia
2001;86:421-33.
74. Crossman AR, Mitchell IJ, Sambrook MA. Regional Brain Uptake of 2-Deoxyglucose in N-Methyl-
4-Phenyl-1,2,3,6-Tetrahydropyridine (Mptp)-Induced Parkinsonism in the Macaque Monkey.
Neuropharmacology 1985;24:587-591.
75. Bergman H, Wichmann T, Karmon B, DeLong MR. The Primate Subthalamic Nucleus. 2.
Neuronal-Activity in the Mptp Model of Parkinsonism. J Neurophysiology 1994;72:507-20.
76. Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, Benabid AL. Subthalamic nucle-
us or internal pallidal stimulation in young onset Parkinson’s disease. Brain 1998;121:451-7.
77. The Deep-Brain Stimulation for Parkinson’s Disease study group. Deep-brain stimulation of the
subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J
Med 2001;345:956-63.
78. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E et al. Effect of parkinso-
nian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345:91-5.
79. Walter BL, Vitek JL. Surgical treatment for Parkinson’s disease. Lancet Neurology 2004;3:719-28.
80. Benazzouz A, Hallett M. Mechanism of action of deep brain stimulation. Neurology 2000;55:S13-
S16.
81. Parent A. Jules Bernard Luys and the subthalamic nucleus. Mov Disord 2002;17:181-5.
82. Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM. The subthalamic nucleus in the context
of movement disorders. Brain 2004;127:4-20.
83. Rodriguez-Oroz MC, Rodriguez M, Guridi J, Mewes K, Chockkman V, Vitek J et al. The subtha-
lamic nucleus in Parkinson’s disease: somatotopic organization and physiological characteristics.
Brain 2001;124:1777-90.
84. Parent A, Hazrati LN. Functional-Anatomy of the Basal Ganglia 2. The Place of Subthalamic
Nucleus and External Pallidum in Basal Ganglia Circuitry. Brain Res Rev 1995;20:128-54.
85. Blandini F, Nappi G, Greenamyre JT. Subthalamic infusion of an NMDA antagonist prevents basal
ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson’s disease. Ann
Neurology 2001;49:525-9.
86. Bevan MD, Wilson CJ. Mechanisms underlying spontaneous oscillation and rhythmic firing in rat
subthalamic neurons. J Neurosci 1999;19:7617-28.
87. Wichmann T, Bergman H, DeLong MR. The Primate Subthalamic Nucleus. 1. Functional
Properties in Intact Animals. J Neurophysiology 1994;72:494-506.
88. Beurrier C, Congar P, Bioulac B, Hammond C. Subthalamic nucleus neurons switch from single-
spike activity to burst-firing mode. J Neurosci 1999;19:599-609.
29
General introduction and aims of the thesis
89. Matsumura M, Kojima J, Gardiner TW, Hikosaka O. Visual and Oculomotor Functions of Monkey
Subthalamic Nucleus. J Neurophysiology 1992;67:1615-32.
90. Orieux G, Francois C, Feger J, Hirsch EC. Consequences of dopaminergic denervation on the
metabolic activity of the cortical neurons projecting to the subthalamic nucleus in the rat. J
Neurosci 2002;22:8762-70.
91. Bezard E, Boraud T, Bioulac B, Gross CE. Involvement of the subthalamic nucleus in glutamater-
gic compensatory mechanisms. Eur J Neurosci 1999;11:2167-70.
92. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D et al. Electrical stimulation
of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 1998;339:1105-11.
93. Deuschl G, Wenzelburger R, Kopper F, Volkmann J. Deep brain stimulation of the subthalamic
nucleus for Parkinson’s disease: a therapy approaching evidence-based standards. J Neurol
2003;250 (Suppl 1):I43-I46.
94. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C et al. Five-year follow-up of
bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med.
2003;349:1925-34.
95. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces
levodopa in Parkinson’s disease: two-year follow-up. Neurology 2002;58:396-401.
96. Fraix V, Pollak P, Van Blercom N, Xie J, Krack P, Koudsie A et al. Effect of subthalamic nucleus
stimulation on levodopa-induced dyskinesia in Parkinson’s disease. Neurology 2000;55:1921-3.
97. Barichella M, Marczewska AM, Mariani C, Landi A, Vairo A, Pezzoli G. Body weight gain rate in
patients with Parkinson’s disease and deep brain stimulation. Mov Disord 2003;18:1337-40.
98. Dujardin K, Defebvre L, Krystkowiak P, Blond S, Destee A. Influence of chronic bilateral stimula-
tion of the subthalamic nucleus on cognitive function in Parkinson’s disease. J Neurol
2001;248:603-11.
99. Bejjani BP, Damier P, Arnulf I, Thivard L, Bonnet AM, Dormont D et al. Transient acute depression
induced by high-frequency deep-brain stimulation. N Engl J Med 1999;340:1476-80.
100. Berney A, Vingerhoets F, Perrin A, Guex P, Villemure JG, Burkhard PR et al. Effect on mood of sub-
thalamic DBS for Parkinson’s disease: a consecutive series of 24 patients. Neurology 2002;59:1427-
9.
101. Kulisevsky J, Berthier ML, Gironell A, Pascual-Sedano B, Molet J, Pares P. Mania following deep
brain stimulation for Parkinson’s disease. Neurology 2002;59:1421-4.
102. Krack P, Ardouin C, Funkiewiez A, Caputo E, Benazzouz A, Benabid A et al. What is the influence
of subthalamic nucleus stimulation on the limbic loop? In: Kultas-Ilinsky K, Ilinsky IA (eds.). Basal
ganglia and thalamus in health and mood disorders. New York: Kluwer Academic/Plenum
Publishers 2001: 333-40.
103. Saint-Cyr JA, Hoque T, Pereira LCM, Dostrovsky JO, Hutchison WD, Mikulis DJ et al. Localization
of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic reso-
nance imaging. J Neurosurgery 2002;97:1152-66.
30
Chapter 1
104. Abosch A, Kapur S, Lang AE, Hussey D, Sime E, Miyasaki J et al. Stimulation of the subthalamic
nucleus in Parkinson’s disease does not produce striatal dopamine relaease. Neurosurgery
2003;53:1095-102.
105. Hilker R, Voges J, Ghaemi M, Lehrke R, Rudolf J, Koulousakis A et al. Deep brain stimulation of
the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian
humans. Mov Disord 2003;18:41-8.
106. Thobois S, Fraix V, Savasta M, Costes N, Pollak P, Mertens P et al. Chronic subthalamic nucleus
stimulation and striatal D2 dopamine receptors in Parkinson’s disease - A [C-11]-raclopride PET
study. J Neurology 2003;250:1219-23.
107. Parkinson’s Disease Study Group. Effects of tocopherol and deprenyl on the progression of dis-
ability in early Parkinson’s disease. N Engl J Med 1993;328:176-83.
108. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J et al. The Effect of Deprenyl
and Levodopa on the Progression of Parkinson’s Disease. Ann Neurol 1995;38:771-7.
109. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S et al.Effects of coenzyme Q10 in early
Parkinson’s disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50.
110. Schapira AHV, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents
in Parkinson’s disease. Ann Neurol 2003;53:S149-S157.
111. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole
vs levodopa on Parkinson’s disease progression. JAMA 2002;287:1653-61.
112. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C et al. Slower progression of
Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol
2003;54:93-101.
113. Marek K, Jennings D, Seibyl J. Dopamine agonists and Parkinson’s disease progression: what can
we learn from neuroimaging studies. Ann Neurol 2003;53 (Suppl 3):S160-S166.
114. Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Sedvall G et al.
Transplantation of Adrenal-Medullary Tissue to Striatum in Parkinsonism. J Neurosurgery
1985;62:169-73.
115. Goetz CG, Olanow CW, Koller WC, Penn RD, Cahill D, Morantz R et al. Multicenter Study of
Autologous Adrenal-Medullary Transplantation to the Corpus Striatum in Patients with
Advanced Parkinson’s Disease. N Engl J Med 1989;320:337-41.
116. Goetz CG, Stebbins GT, Klawans HL, Koller WC, Grossman RG, Bakay RAE et al. United-
Parkinson’s Foundation Neurotransplantation Registry on Adrenal-Medullary Transplants -
Presurgical, and 1-Year and 2-Year Follow-Up. Neurology 1991;41:1719-22.
117. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R et al. Transplantation of embry-
onic dopamine neurons for severe Parkinson’s disease. N Eng J Med 2001;344:710-9.
118. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF et al. A double-blind controlled
trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003;54:403-14.
31
General introduction and aims of the thesis
119. Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK et al. Transplantation of
embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000;54:1042-50.
120. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER et al. Randomized, double-blind
trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73.
121. Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M et al. Direct brain infusion of
glial cell line-derived neurotrophic factor in Parkinson’s disease. Nature Medicine 2003;9:589-95.
122. Smith Y, Charara A, Parent A. Synaptic innervation of midbrain dopaminergic neurons by gluta-
mate-enriched terminals in the squirrel monkey. J Compar Neurol 1996;364:231-53.
123. Smith ID, Grace AA. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron
activity. Synapse 1992;12:287-303.
124. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in
Parkinson’s disease: a target for neuroprotection. Ann Neurol 1998;44:S175-S188.
125. Macdonald JF, Nowak LM. Mechanisms of Blockade of Excitatory Amino-Acid Receptor
Channels. Trends Pharmacol  Sci 1990;11:167-72.
126. Mareysemper I, Gelman M, Levistrauss M. A Selective Toxicity Toward Cultured Mesencephalic
Dopaminergic Neurons Is Induced by the Synergistic Effects of Energetic Metabolism Impairment
and Nmda Receptor Activation. J Neurosci 1995;15:5912-8.
127. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate Becomes Neurotoxic Via the N-
Methyl-D-Aspartate Receptor When Intracellular Energy Levels Are Reduced. Brain Research
1988;451:205-12.
128. Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic
nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistoche-
mical studies. Eur J Neurosci. 1996;8:1408-14.
129. Nakao N, Nakai E, Nakai K, Itakura T. Ablation of the subthalamic nucleus supports the survival
of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-
nitropropionic acid. Ann Neurol 1999;45:640-51.
130. Brooks DJ. The early diagnosis of Parkinson's disease. Ann Neurol 1998;44:S10-S18.
131. Volkow ND, Fowler JS, Gatley SJ, Logan J, Wang GJ, Ding YS et al. PET evaluation of the
dopamine system of the human brain. J Nucl Med 1996;37:1242-56.
132. Hoffman  JM, Hanson MW, Coleman RE. Clinical positron emission tomography imaging.
Radiologic Clinics of North America, 1983;31. 
133. Phelps ME. PET: a biological imaging technique. Neurochem Res 1991;16:929-40.
134. Brooks DJ. Advances in imaging Parkinson's disease. Curr Opin Neurol 1997;10:327-31.
135. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmis-
sion system using single-photon emission tomography and positron emission tomography in
patients with parkinsonism. Eur J Nucl Med 1999;26:171-82.
32
Chapter 1
136. Garnett ES, Firnau G, Nahmias C. Dopamine Visualized in the Basal Ganglia of Living Man.
Nature 1983;305:137-8.
137. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES et al. Brain Dopamine
Metabolism in Patients with Parkinson’s Disease Measured with Positron Emission Tomography.
J Neurol Neurosurg Psychiatry 1986;49:853-60.
138. Eckert T, Eidelberg D. The role of functional neuroimaging in the differential diagnosis of idio-
pathic Parkinson's disease and multiple system atrophy. Clin Auton Res 2004;14:84-91.
139. Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H et al. Human positron emis-
sion tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann
Neurol 1993;34:324-30.
140. Antonini A, DeNotaris R. PET and SPECT functional imaging in Parkinson's disease. Sleep Med
2004;5:201-6.
141. Leenders KL. Dopamine metabolism in brain studied with PET. In: Bunney, Hippius, Laakmann,
Schmauss, eds. Neuropsychopharmacology. Springer-Verlag 1990: 418-28.
142. Bhatt MH, Snow BJ, Martin WRW, Pate BD, Calne DB. Positron Emission Tomography Suggests
That the Rate of Progression of Idiopathic Parkinsonism Is Slow. Ann Neurol 1991;29:673-7.
143. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal Fluorodopa
Positron Emission Tomographic Studies of the Evolution of Idiopathic Parkinsonism. Ann Neurol
1994;36:759-64.
144. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression
in Parkinson's disease. Brain 1996;119:585-91.
145. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and
estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg
Psychiatry 1998;64:314-9.
146. Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P et al. Rate of progression
in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001;16:608-15.
